Click here to get full coverage on CADL stock gets a bullish call just weeks before crucial prostate cancer data reveal - MSN

CADL stock gets a bullish call just weeks before crucial prostate cancer data reveal  MSN

CADL stock gets a bullish call just weeks before crucial prostate cancer data reveal - MSN

Click here to get full coverage on BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan

BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL)  Stock Titan

BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan

Click here to get full coverage on $CADL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

$CADL stock is down 8% today. Here's what we see in our data.  Quiver Quantitative

$CADL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily

How (CADL) Movements Inform Risk Allocation Models  Stock Traders Daily

How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily

Click here to get full coverage on CADL exploring former Gibson's Bookstore space for downtown Lansing branch - WKAR

CADL exploring former Gibson's Bookstore space for downtown Lansing branch  WKAR

CADL exploring former Gibson's Bookstore space for downtown Lansing branch - WKAR

Click here to get full coverage on Celebrate Libraries Week with CADL - WILX

Celebrate Libraries Week with CADL  WILX

Celebrate Libraries Week with CADL - WILX

Click here to get full coverage on CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?  Stocktwits

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits

Click here to get full coverage on CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside? - Stocktwits

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside?  Stocktwits

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside? - Stocktwits

Click here to get full coverage on CADL stock on track for best day in nearly 16 months — what’s driving the rally? - MSN

CADL stock on track for best day in nearly 16 months — what’s driving the rally?  MSN

CADL stock on track for best day in nearly 16 months — what’s driving the rally? - MSN

Click here to get full coverage on Dow, S&P 500, Nasdaq futures rise as traders eye Supreme Court tariff verdict, GDP data: Why GRAL, RIG, CADL, CELH, ARDX are trending - MSN

Dow, S&P 500, Nasdaq futures rise as traders eye Supreme Court tariff verdict, GDP data: Why GRAL, RIG, CADL, CELH, ARDX are trending  MSN

Dow, S&P 500, Nasdaq futures rise as traders eye Supreme Court tariff verdict, GDP data: Why GRAL, RIG, CADL, CELH, ARDX are trending - MSN

Click here to get full coverage on Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today  Stocktwits

Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits

Click here to get full coverage on Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term  Yahoo Finance

Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance

Click here to get full coverage on Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL) - Seeking Alpha

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL)  Seeking Alpha

Candel Therapeutics: 'Cancer Vaccine' Buy Thesis Appears Compelling (NASDAQ:CADL) - Seeking Alpha

Click here to get full coverage on Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan

Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees  Stock Titan

Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan

Click here to get full coverage on Candel gives five new hires options for 70,000 shares at $4.90 - Stock Titan

Candel gives five new hires options for 70,000 shares at $4.90  Stock Titan

Candel gives five new hires options for 70,000 shares at $4.90 - Stock Titan

Click here to get full coverage on Capital Area District Libraries announces plan to relocate Local History collection - WILX

Capital Area District Libraries announces plan to relocate Local History collection  WILX

Capital Area District Libraries announces plan to relocate Local History collection - WILX

Click here to get full coverage on Candel plans 2027 prostate cancer launch, funds trials into 2028 - Stock Titan

Candel plans 2027 prostate cancer launch, funds trials into 2028  Stock Titan

Candel plans 2027 prostate cancer launch, funds trials into 2028 - Stock Titan

Click here to get full coverage on CADL Initiated Coverage By Cantor Fitzgerald -- Rating Overweigh - GuruFocus

CADL Initiated Coverage By Cantor Fitzgerald -- Rating Overweigh  GuruFocus

CADL Initiated Coverage By Cantor Fitzgerald -- Rating Overweigh - GuruFocus

Click here to get full coverage on Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan

Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options  Stock Titan

Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan

Click here to get full coverage on Paradigm-shifting prostate cancer trial data to debut at AUA 2026 - Stock Titan

Paradigm-shifting prostate cancer trial data to debut at AUA 2026  Stock Titan

Paradigm-shifting prostate cancer trial data to debut at AUA 2026 - Stock Titan

Click here to get full coverage on Trading Systems Reacting to (CADL) Volatility - Stock Traders Daily

Trading Systems Reacting to (CADL) Volatility  Stock Traders Daily

Trading Systems Reacting to (CADL) Volatility - Stock Traders Daily

Click here to get full coverage on Cancer-drug maker Candel plans $100M sale for prostate, lung push - Stock Titan

Cancer-drug maker Candel plans $100M sale for prostate, lung push  Stock Titan

Cancer-drug maker Candel plans $100M sale for prostate, lung push - Stock Titan

Click here to get full coverage on Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com

Paul Manning buys Candel Therapeutics (CADL) shares worth $3m  Investing.com

Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com

Click here to get full coverage on Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan

Candel Therapeutics (CADL) director granted 4,618 fully vested stock options  Stock Titan

Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan

Click here to get full coverage on Half of lung cancer patients alive 2 years in Candel immunotherapy study - Stock Titan

Half of lung cancer patients alive 2 years in Candel immunotherapy study  Stock Titan

Half of lung cancer patients alive 2 years in Candel immunotherapy study - Stock Titan

Click here to get full coverage on Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating - Benzinga

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating  Benzinga

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating - Benzinga

Click here to get full coverage on Cantor Fitzgerald initiates coverage of Candel Therapeutics (CADL) with overweight recommendation - MSN

Cantor Fitzgerald initiates coverage of Candel Therapeutics (CADL) with overweight recommendation  MSN

Cantor Fitzgerald initiates coverage of Candel Therapeutics (CADL) with overweight recommendation - MSN

Click here to get full coverage on CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Hot Momentum Watchlist - UBND thành phố Hải Phòng

CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Hot Momentum Watchlist  UBND thành phố Hải Phòng

CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Hot Momentum Watchlist - UBND thành phố Hải Phòng

Click here to get full coverage on Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan

Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial  Stock Titan

Cancer biotech Candel prices $100M sale to back prostate launch prep, lung trial - Stock Titan

Click here to get full coverage on Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan

Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares  Stock Titan

Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan

Click here to get full coverage on Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages  MarketBeat

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages - MarketBeat

Click here to get full coverage on Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell - MarketBeat

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell  MarketBeat

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell - MarketBeat

Click here to get full coverage on Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st

Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL)  simplywall.st

Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st

Click here to get full coverage on CADL offers 6 great reads that show women have always been part of the story - Lansing State Journal

CADL offers 6 great reads that show women have always been part of the story  Lansing State Journal

CADL offers 6 great reads that show women have always been part of the story - Lansing State Journal

Click here to get full coverage on $130M term loan gives Candel Therapeutics $50M now to fund Phase 3 CAN-2409 in NSCLC - Stock Titan

$130M term loan gives Candel Therapeutics $50M now to fund Phase 3 CAN-2409 in NSCLC  Stock Titan

$130M term loan gives Candel Therapeutics $50M now to fund Phase 3 CAN-2409 in NSCLC - Stock Titan

Click here to get full coverage on New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan

New Candel Therapeutics hire gets 20,000 stock options at $5.25  Stock Titan

New Candel Therapeutics hire gets 20,000 stock options at $5.25 - Stock Titan

Click here to get full coverage on Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m - simplywall.st

Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m  simplywall.st

Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m - simplywall.st

Click here to get full coverage on New Candel hire receives 6,600 stock options as joining inducement - Stock Titan

New Candel hire receives 6,600 stock options as joining inducement  Stock Titan

New Candel hire receives 6,600 stock options as joining inducement - Stock Titan

Click here to get full coverage on Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan

Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust  Stock Titan

Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan

Click here to get full coverage on CADL offers six new reads for Black History Month - Lansing State Journal

CADL offers six new reads for Black History Month  Lansing State Journal

CADL offers six new reads for Black History Month - Lansing State Journal

Click here to get full coverage on Candel Therapeutics prices $100M public offering - Proactive financial news

Candel Therapeutics prices $100M public offering  Proactive financial news

Candel Therapeutics prices $100M public offering - Proactive financial news

Click here to get full coverage on Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL - Proactive financial news

Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL  Proactive financial news

Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit | NASDAQ:CADL - Proactive financial news

Click here to get full coverage on Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering - Proactive financial news

Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering  Proactive financial news

Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering - Proactive financial news

Click here to get full coverage on Candel Therapeutics (CADL) Stock Analysis: A Biotech With A 236% Upside Potential - DirectorsTalk Interviews

Candel Therapeutics (CADL) Stock Analysis: A Biotech With A 236% Upside Potential  DirectorsTalk Interviews

Candel Therapeutics (CADL) Stock Analysis: A Biotech With A 236% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on Hot reads for long summer days: CADL literary experts share recommendations - Lansing State Journal

Hot reads for long summer days: CADL literary experts share recommendations  Lansing State Journal

Hot reads for long summer days: CADL literary experts share recommendations - Lansing State Journal

Click here to get full coverage on Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?  Yahoo Finance

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai

CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Most Discussed Stocks  Cổng thông tin điện tử tỉnh Lào Cai

CADL (Candel Therapeutics Inc.) reports wide Q4 2025 EPS miss while notching slight share gains on stable investor sentiment. - Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Click here to get full coverage on Candel Therapeutics strengthens balance sheet as lead cancer therapy advances | NASDAQ:CADL - Proactive financial news

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances | NASDAQ:CADL  Proactive financial news

Candel Therapeutics strengthens balance sheet as lead cancer therapy advances | NASDAQ:CADL - Proactive financial news

Click here to get full coverage on Insider Stock Purchases: February 27, 2026 - Quiver Quantitative

Insider Stock Purchases: February 27, 2026  Quiver Quantitative

Insider Stock Purchases: February 27, 2026 - Quiver Quantitative

Click here to get full coverage on Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now  Seeking Alpha

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha

Click here to get full coverage on Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha

Candel Therapeutics: Potentially The Next Exciting Oncology Story  Seeking Alpha

Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha

Click here to get full coverage on Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment - Stock Titan

Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment  Stock Titan

Candel Therapeutics Raises $15M with Strong Insider Backing to Advance Prostate Cancer Treatment - Stock Titan

Click here to get full coverage on Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news

Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409  Proactive financial news

Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news

Click here to get full coverage on Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative

Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025  Quiver Quantitative

Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative

Click here to get full coverage on Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade

Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement  StocksToTrade

Candel Therapeutics Faces Mixed Sentiments After Secondary Offering Announcement - StocksToTrade

Click here to get full coverage on Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com

Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering  timothysykes.com

Candel Therapeutics Faces Strategic Financial Moves Amidst Stock Offering - timothysykes.com

Click here to get full coverage on Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures  simplywall.st

Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Click here to get full coverage on Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView

Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds  TradingView

Candel Therapeutics Prices 18.35M-Share Offering at $5.45, Expects ~$93.5M Net Proceeds - TradingView

Click here to get full coverage on Candel Therapeutics Strikes $100 Million Royalty Financing With RTW Tied to CAN-2409 Approval - TradingView

Candel Therapeutics Strikes $100 Million Royalty Financing With RTW Tied to CAN-2409 Approval  TradingView

Candel Therapeutics Strikes $100 Million Royalty Financing With RTW Tied to CAN-2409 Approval - TradingView

Click here to get full coverage on Key facts: Candel Therapeutics secures $100M funding; plans drug launches - TradingView

Key facts: Candel Therapeutics secures $100M funding; plans drug launches  TradingView

Key facts: Candel Therapeutics secures $100M funding; plans drug launches - TradingView

Click here to get full coverage on Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news

Candel Therapeutics CEO to present at TD Cowen health care conference on March 3  Proactive financial news

Candel Therapeutics CEO to present at TD Cowen health care conference on March 3 - Proactive financial news

Click here to get full coverage on Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations - StocksToTrade

Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations  StocksToTrade

Candel Therapeutics Initiates $100M Stock Offering Amid Market Fluctuations - StocksToTrade

Click here to get full coverage on CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - Yahoo Finance

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer  Yahoo Finance

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - Yahoo Finance

Click here to get full coverage on ‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience - Lansing State Journal

‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience  Lansing State Journal

‘Better Living Through Birding’ chosen for Greater Lansing shared reading experience - Lansing State Journal

Click here to get full coverage on Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks

Candel Therapeutics Announces Equity Offering to Fund CAN-2409  TipRanks

Candel Therapeutics Announces Equity Offering to Fund CAN-2409 - TipRanks

Click here to get full coverage on Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending - Stocktwits

Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending  Stocktwits

Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending - Stocktwits

Click here to get full coverage on Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)  The Globe and Mail

CADL

Price Chart

Key Statistics

Technicals

About CADL

Latest News

CADL stock gets a bullish call just weeks before crucial prostate cancer data reveal - MSN

BlackRock files Schedule 13G/A reporting 3,079,861 CADL shares (NYSE: CADL) - Stock Titan

$CADL stock is down 8% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers